The Market
Mass tort litigation aggregates large numbers of individually filed claims arising from a common product, exposure, or course of conduct, coordinated through multidistrict litigation, state court consolidations, or bellwether trial programs. As a regulated outcomes market it behaves differently from single-plaintiff litigation: the unit of analysis is not one case but a cohort, and the outcome distribution for any individual claimant is shaped heavily by how bellwether trials perform, how a settlement matrix values injury tiers, and how quickly the defendant and plaintiffs' leadership move toward a global resolution once liability exposure becomes clear.
Duration in mass tort is measured in years rather than months, and it moves in discrete phases: case consolidation, bellwether selection and trial, and settlement matrix negotiation each reset the timeline. That phase structure is itself a data problem: the signal that a docket is entering settlement posture arrives well before any individual claim resolves, and identifying it early is where capital efficiency is won or lost.
Because a mass tort docket can run for the better part of a decade, the cost of misreading its current phase compounds. Capital committed on the assumption that a docket is two years from resolution, when it is in fact entering an accelerated settlement posture following favorable bellwether results, sits deployed longer than necessary. Capital withheld on the opposite misreading misses the window when case-cost financing is most valuable to the firms carrying the docket forward.
Counterparties
Plaintiffs' firms operating at scale, often in leadership or steering committee roles within the MDL; litigation funders providing case-cost and law firm capital across the docket; defendants and their insurers managing aggregate exposure; claims administrators who process the eventual settlement matrix; medical and lien intermediaries managing the Medicare, Medicaid, and private lien exposure that attaches to injury claims at settlement; and the judiciary managing coordination through pretrial orders and bellwether selection. The capital relationship in mass tort is typically with the law firm or portfolio holder rather than the individual claimant, which changes the underwriting unit from a single case to a book of cases.
Referral networks also play an outsized role in this vertical relative to single-plaintiff litigation. Claimant intake for a mass tort docket frequently flows through intermediary marketing and referral organizations rather than direct client relationships, which adds a counterparty layer, and a corresponding integrity question, that most other verticals on this page do not carry in the same volume or concentration.
What Decides Outcome, Duration, and Settlement
The central questions are docket-level rather than claim-level: what phase is this MDL in, what does bellwether trial performance signal about the eventual settlement matrix, what is the probability distribution of injury-tier valuation once a matrix is set, and when does the defendant's aggregate exposure calculus tip toward a global settlement rather than continued individual trials. A law firm's or portfolio holder's case-cost capital needs are driven by docket volume and phase, not by any single claimant's facts, so duration and settlement-timing intelligence at the docket level is the primary underwriting input.
Bellwether selection itself carries information value beyond the individual trial outcome. Which cases are chosen as bellwethers, by whom, and on what criteria signals how both sides are reading the broader docket's risk profile, and a shift in bellwether selection strategy midstream is often an early indicator of a phase transition well before either side states its position publicly.
How Criterica Serves This Market
Criterica Intelligence tracks docket-level phase signals, bellwether outcomes, and settlement-matrix patterns across active multidistrict litigation, giving funders and law firms an outcome and timing view built from the docket rather than any single file. Criterica Capital finances mass tort exposure through law firm capital and portfolio structures sized to docket phase and volume rather than individual case review. Criterica Group's integrity standard applies at the portfolio level here specifically: concentration in one defendant, one provider, or one referral source is a portfolio-level integrity signal in mass tort in a way it is not in single-plaintiff litigation, and the standard requires it be monitored as such.
Referral-network integrity is treated as a first-class monitoring question rather than a secondary concern, given how much intake in this vertical depends on intermediary marketing organizations. A portfolio drawing an unusual share of its claimant volume from a small number of referral sources is a concentration risk independent of the underlying legal merits, and it is monitored as one.
Data: What Exists, What Does Not
Federal MDL dockets, pretrial order histories, and bellwether verdict reporting are public and trackable, and settlement matrices become public once a global resolution is reached. What is harder to obtain, and what most differentiates a serious mass tort intelligence capability, is real-time visibility into claim volume and injury-tier composition before a matrix is finalized, since individual firms and administrators hold that data privately during the active phase of a docket.
Claimant-level intake and referral data is similarly private during a docket's active phase, held across dozens of individual firms and referral organizations rather than in any centralized system, which is why portfolio-level concentration risk in this vertical has historically been harder to see from the outside than duration or bellwether-outcome risk.
Discuss Mass Tort
Capital partners, law firms, insurers, and institutional buyers evaluating this market.